Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas Sells 783 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas sold 783 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $28.70, for a total value of $22,472.10. Following the completion of the transaction, the chief accounting officer now directly owns 37,358 shares in the company, valued at $1,072,174.60. The trade was a 2.05 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Apellis Pharmaceuticals Trading Down 3.1 %

Shares of APLS stock opened at $27.69 on Wednesday. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The firm has a fifty day moving average of $31.86 and a 200-day moving average of $33.48. Apellis Pharmaceuticals, Inc. has a 52-week low of $24.34 and a 52-week high of $71.90. The stock has a market cap of $3.44 billion, a price-to-earnings ratio of -13.64 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The business had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. During the same quarter in the prior year, the business earned ($1.17) EPS. The firm’s revenue for the quarter was up 78.3% on a year-over-year basis. On average, equities research analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on APLS. Oppenheimer lowered their price target on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. The Goldman Sachs Group downgraded shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 target price on the stock. in a report on Tuesday, December 17th. Robert W. Baird decreased their price target on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday. Finally, Evercore ISI upgraded Apellis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, October 31st. Eight equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $46.65.

Institutional Trading of Apellis Pharmaceuticals

A number of large investors have recently bought and sold shares of APLS. Wolverine Asset Management LLC bought a new position in shares of Apellis Pharmaceuticals during the third quarter valued at $27,000. True Wealth Design LLC bought a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter worth about $27,000. Capital Performance Advisors LLP acquired a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter worth about $56,000. KBC Group NV lifted its holdings in Apellis Pharmaceuticals by 34.8% during the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock valued at $76,000 after purchasing an additional 679 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Apellis Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after purchasing an additional 781 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).